Finally, to address whether a concomitant decrease in RBM25 expression and activation of MYC targets is associated with specific AML subtypes we partitioned the TCGA dataset into two distinct groups: Group 1 contains patients which display low expression of RBM25 (low 25% percentile) and high level of MYC target gene expression (MYC target gene score > median) and Group 2 containing patients with the opposite characteristics. The gene discussed is RBM25; the disease is acute myeloid leukemia.